The aryl propionic acid R-flurbiprofen selectively induces p75 NTR-dependent decreased survival of prostate tumor cells

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3254-3262

  Quann, Emily J ^a   Khwaja, Fatima ^a   Zavitz, Kenton H ^c   Djakiew, Daniel ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c Myriad Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLPROPIONIC ACID DERIVATIVE; DEATH RECEPTOR; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; KETOPROFEN; NAPROXEN; OXAPROZIN; PROTEIN P75; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGFR PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL STRAIN LNCAP; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLURBIPROFEN; HUMANS; IBUPROFEN; MALE; NERVE TISSUE PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, NERVE GROWTH FACTOR; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 34248222508     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3657     Document Type: Article

References (54)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.
3. Garcia LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:649-53.
4. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219-25.
5. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7:169-70.
6. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002;13:427-34.
7. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245-9.
8. Gavrilov V, Steiner M, Shany S. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res 2005;25:3425-9.
9. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
10. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-8.
11. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000;56:671-6.
12. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000;86:736-41.
13. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617-23.
14. Shappell SB, Manning S, Boeglin WE, et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 2001;3:287-303.
15. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-α in normal and malignant prostate cells. Cancer Res 2001; 61:2720-6.
16. Lee JH, Cheong J, Park YM, Choi YH. Down-regulation of cyclooxygenase-2 and telomerase activity by β-lapachone in human prostate carcinoma cells. Pharmacol Res 2005;51:553-60.
17. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
18. Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-91.
19. Farivar-Mohseni H, Kandzari SJ, Zaslau S, Riggs DR, Jackson BJ, McFadden DW. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. Am J Surg 2004;188:505-10.
20. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
21. Andrews J, Djakiew D, Krygier S, Andrews P. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 2002;50:277-84.
22. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23:9247-58.
23. Chao MV. The p75 neurotrophin receptor. J Neurobiol 1994;25:1373-85.
24. Chapman BS. A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas. FEBS Lett 1995;374:216-20.
25. Friedman WJ, Greene LA. Neurotrophin signaling via Trks and p75. Exp Cell Res 1999;253:131-42.
26. Pflug B, Djakiew D. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death. Mol Carcinog 1998;23:106-14.
27. Krygier S, Djakiew D. The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. Anticancer Res 2001;21:3749-55.
28. Krygier S, Djakiew D. Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 2002;98:1-7.
29. Khwaja F, Tabassum A, Allen J, Djakiew D. The p75(NTR) tumor suppressor induces cell cycle arrest facilitating caspase mediated apoptosis in prostate tumor cells. Biochem Biophys Res Commun 2006;341:1184-92.
30. Perez M, Regan T, Pflug B, Lynch J, Djakiew D. Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 1997;30:274-9.
31. Krygier S, Djakiew D. Molecular characterization of the loss of p75(NTR) expression in human prostate tumor cells. Mol Carcinog 2001;31:46-55.
32. Allen J, Khwaja F, Byers S, Djakiew D. The p75NTR mediates a bifurcated signal transduction cascade through the NFκB and JNK pathways to inhibit cell survival. Exp Cell Res 2005;304:69-80.
33. Khwaja F, Allen J, Lynch J, Andrews P, Djakiew D. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. Cancer Res 2004;64:6207-13.
34. Wechter WJ, Leipold DD, Murray ED, Jr., et al. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000;60:2203-8.
35. Wang X, Bauer JH, Li Y, et al. Characterization of a p75(NTR) apoptotic signaling pathway using a novel cellular model. J Biol Chem 2001;276:33812-20.
36. Evans AM. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol 1996;36:7-15S.
37. Landoni MF, Soraci A. Pharmacology of chiral compounds: 2-arylpropionic acid derivatives. Curr Drug Metab 2001;2:37-51.
38. Rovensky J, Micekova D. Six-month prospective study to monitor the treatment of rheumatic diseases with sustained-release flurbiprofen. Drugs Exp Clin Res 2000; 26:19-24.
39. Kean WF. Oxaprozin: kinetic and dynamic profile in the treatment of pain. Curr Med Res Opin 2004;20:1275-7.
40. Grahame R. Ketoprofen-clinical efficacy. Rheumatol Rehabil 1976;Suppl:22-6.
41. Ward JR. Update on ibuprofen for rheumatoid arthritis. Am J Med 1984;77:3-9.
42. Sigler JW, Ridolfo AS, Bluhm GB. Comparison of benefit-to-risk ratios of aspirin and fenoprofen: controlled multicentre study in rheumatoid arthritis. J Rheumatol 1976;2:49-60.
43. Lee P, Rose BS, Anderson JA, Caughey DE. Naproxen in the treatment of rheumatoid arthritis. N Z Med J 1978;87:425-7.
44. Wargovich MJ, Jimenez A, McKee K, et al. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 2000; 21:1149-55.
45. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
46. Castonguay A, Rioux N, Duperron C, Jalbert G. Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 1998;24:605-15.
47. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274: 8328-34.
48. Yuan CJ, Mandal AK, Zhang Z, Mukherjee AB. Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs. Cancer Res 2000;60:1084-91.
49. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin Cancer Res 2003;9:3150-7.
50. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60.
51. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
52. Zhang M, Abe Y, Matsushima T, Nishimura J, Nawata H, Muta K. Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. Leuk Lymphoma 2005;46:425-33.
53. Huang Y, He Q, Hillman MJ, Rong R, Sheikh MS. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 2001;61:6918-24.
54. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.